RET and neoplasm: Despite this prior therapy-mediated serial genetic evolution of RET, the plasma frequency of both the enrolling and secondary RET mutations decreased with selpercatinib treatment in all patients, indicating that the tumor cell with both RET alterations remained sensitive to RET inhibition (Fig. 2d).